{"id":"tafenoquine-oral-tablet","safety":{"commonSideEffects":[{"rate":"null","effect":"Hemolysis"},{"rate":"null","effect":"Neurological effects"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tafenoquine is a 8-aminoquinoline that accumulates in the food vacuole of the Plasmodium parasite, where it inhibits the enzyme dihydroorotate dehydrogenase, disrupting the parasite's heme detoxification pathway and ultimately leading to the parasite's death.","oneSentence":"Tafenoquine is an antimalarial drug that works by targeting the Plasmodium parasite's heme detoxification pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:26.207Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of malaria"}]},"trialDetails":[{"nctId":"NCT07373743","phase":"EARLY_PHASE1","title":"Pharmacokinetic (PK) Study of Tafenoquine in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"State University of New York - Upstate Medical University","startDate":"2026-05","conditions":"Pharmacokinetic in Normal Population","enrollment":20},{"nctId":"NCT07060404","phase":"PHASE2, PHASE3","title":"Postpartum 8-aminoquinoline Breast Milk Study","status":"NOT_YET_RECRUITING","sponsor":"Curtin University","startDate":"2026-04","conditions":"Drug Pharmacokinetics in Healthy Volunteers","enrollment":60},{"nctId":"NCT06478641","phase":"","title":"Expanded Use in Persistent (B. Microti) Babesiosis","status":"AVAILABLE","sponsor":"60 Degrees Pharmaceuticals LLC","startDate":"","conditions":"Persistent Babesiosis","enrollment":""},{"nctId":"NCT06656351","phase":"PHASE2","title":"B-FREE Chronic Babesiosis Study","status":"RECRUITING","sponsor":"60 Degrees Pharmaceuticals LLC","startDate":"2025-11-18","conditions":"Chronic Babesiosis","enrollment":40},{"nctId":"NCT06207370","phase":"PHASE2","title":"Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis","status":"RECRUITING","sponsor":"60 Degrees Pharmaceuticals LLC","startDate":"2024-06-17","conditions":"Babesiosis","enrollment":33},{"nctId":"NCT05540470","phase":"NA","title":"Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield","status":"COMPLETED","sponsor":"Centre Hospitalier de Cayenne","startDate":"2022-09-12","conditions":"Malaria, Vivax","enrollment":1991},{"nctId":"NCT05788094","phase":"PHASE4","title":"ACT vs CQ With Tafenoquine for P. Vivax Mono-infection","status":"RECRUITING","sponsor":"Shoklo Malaria Research Unit","startDate":"2023-06-26","conditions":"Malaria, Malaria, Vivax, Plasmodium Vivax Malaria","enrollment":606},{"nctId":"NCT04533347","phase":"PHASE2","title":"Tafenoquine in Patients With Mild to Moderate COVID-19","status":"COMPLETED","sponsor":"60 Degrees Pharmaceuticals LLC","startDate":"2021-02-19","conditions":"COVID 19 Disease","enrollment":86},{"nctId":"NCT05947812","phase":"PHASE2","title":"A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression","status":"UNKNOWN","sponsor":"60P Australia Pty Ltd","startDate":"2023-08-01","conditions":"COVID 19 Disease, Mild to Moderate COVID 19 Disease, SARS-CoV-2","enrollment":148},{"nctId":"NCT02802501","phase":"PHASE3","title":"Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-08","conditions":"Malaria, Vivax","enrollment":150},{"nctId":"NCT02216123","phase":"PHASE3","title":"Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-04-30","conditions":"Malaria, Vivax","enrollment":251},{"nctId":"NCT02658435","phase":"PHASE1","title":"Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-02-02","conditions":"Malaria, Vivax","enrollment":486},{"nctId":"NCT02184637","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-31","conditions":"Malaria, Vivax","enrollment":120},{"nctId":"NCT02751294","phase":"PHASE1","title":"A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05","conditions":"Malaria, Vivax","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["KODATEF™","Arakoda","ARAKODA™"],"phase":"phase_3","status":"active","brandName":"Tafenoquine Oral Tablet","genericName":"Tafenoquine Oral Tablet","companyName":"State University of New York - Upstate Medical University","companyId":"state-university-of-new-york-upstate-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tafenoquine is an antimalarial drug that works by targeting the Plasmodium parasite's heme detoxification pathway. Used for Treatment of malaria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}